Advantages of India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India India Clinical Trials.

Slides:



Advertisements
Similar presentations
Ranbaxy Laboratories Limited Differential Pricing & Financing of Essential Drugs Experience with Generic drugs Cecile H Miles Head of Western Europe Division.
Advertisements

1 FIRST QUARTER 2009 INVESTOR CONFERENCE CALL. 2 Today ’ s Hosts Steve Romano Chairman & Chief Executive Officer Jim Baumgardner President & Chief Operating.
1 Agenda Business Overview Operational & Financial Performance - ICICI Limited Asset Composition and Quality - ICICI Limited Capital and Shareholders -
Computing Research in Latin America Jaime Puente Program Manager External Research & Programs Microsoft Research Jaime Puente Program Manager External.
Pharmaceuticals Limited India – CIS International Pharma Conference 3-5 th March 2006, Mumbai Prashant Nagre Vice President – API Division.
Your Future Can you see it? What does it look like?
Hale & Tempest The Global Pharmaceutical Industry (MNC & Generic) in Transition Dr. Brian W Tempest The Global Generic Summit – Barcelona,
Standard Register Fourth Quarter and Full Year 2007 Conference Call February 22, 2008.
ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010.
1 ICON Plc. Merrill Lynch - Global Pharmaceutical, Biotech & Medtech Conference, September 19 th 2007.
The Challenges from India in the Global Generic Market Place Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories.
The Role of Generics in Reducing the Cost of Healthcare Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited,
Hale & Tempest Understanding the Strategies Big Pharma are Developing to win in the Global Generics Market Dr. Brian W Tempest Istanbul,
Cross Cultural Workforce Engagement Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India.
Views on the Generics Market Dr Brian Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories, Delhi, India EGA Conference Istanbul,
Structure of Indian Economy. EVEN THOUGH THE WORLD HAS JUST DISCOVERED IT, THE INDIA GROWTH STORY IS NOT NEW. IT HAS BEEN GOING ON FOR 25 YEARS OLD.
Shortage of Natural Resources The Scientific Innovative Power coming from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board.
Hale & Tempest Trends in the Pharmaceutical Industry and the Potential Impact on Future Innovation and Access to Medicines Dr. Brian W Tempest
Industry Trends and Tools for Generic Product Selection KATE KUHRT SHANGHAI JUNE 19-21, 2007.
Critical Success Factors for the Korean Generic and API Industry in a post FTA Environment DAVID HARDING SEOUL JUNE 28-29, 2007.
February Forward-Looking Statement Statements at this meeting that are not historical are forward-looking and are subject to various risks and.
Hale & Tempest Trends in the Pharmaceutical Industry and the Potential Impact on Future Innovation and Access to Medicines Dr. Brian W Tempest
Skycargo.com Ram C. Menen Divisional Senior Vice President Cargo Mumbai, India 24 th January 2008 Emerging Market: The Road Ahead.
The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Mumbai – September.
Professor Song CHEN, Ph.D. Deputy Dean, School of Economics & Management Tongji University Oct. 7, 2013 The Changing National.
Hale & Tempest India Biotech Briefing Dr. Brian W Tempest IBIZ Conference, NHS Expo Excel London UK 9 March 2011.
Presentation to the Chinese Institute of Certified Public Accountants Beijing September 2012 Supporting International Development by China’s Corporate.
The New Economic Landscape Brian W Tempest CEO & Managing Director Ranbaxy Laboratories Limited, India The Pharmaceutical Industry in the 21 st Century.
The Rise of China & India. Rapid Economic Growth in China Economic Growth rates of 9.5% are expected to continue Economic Growth rates of 9.5% are expected.
The Emerging High Tech Competitors from Asia, Contrasts between the national systems of innovation and its performance of China and India Professor Sunil.
BP Biofuels a growing alternative Phil New, CEO BP Alternative Energy 9 July 2013.
Hale & Tempest Trends in the Pharmaceutical Industry and the Potential Impact on Future Innovation and Access to Medicines Dr. Brian W Tempest
Reflections on the Global Generic Pharmaceuticals Market place Dr. Brian W Tempest Vidya Pratishthan’s School of Biotechnology, Baramati,
Is Asia the Answer? Dr. Brian W Tempest The 2008 IMS Pharma Strategy Conference New York –12 th February 2008.
Hale & Tempest Global Pharma 2014 Dr. Brian W Tempest Mumbai August 2014.
Hale & Tempest Inhalation Drug Delivery Conference Dr. Brian W Tempest CpHI Ramada Hotel, Berlin, Germany 11 September 2013.
1 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference 2008 Dr. John Climax Executive Chairman.
Partners in Globalisation UK Trade & Investment British Business Group in Mumbai & Pune Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the.
The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Zurich – October.
Certain information contained in this presentation may constitute forward-looking statements subject to the Safe Harbor Provision of the Private Securities.
Reflections on the Global Generic Pharmaceuticals Market place Dr. Brian W Tempest CII Pharma Summit Mumbai Thursday November 1 st.
Hale & Tempest India UKIBC Briefing Dr. Brian W Tempest UK India Business Council Manchester 10 March 2011.
Global Recognition of the Indian Biotech Sector - The Road Ahead Sept 26,2003 Hyderabad.
Sustaining America’s High Tech Future Innovation and STEM Competitiveness Presented by Marjorie Bynum Vice President, Globally Competitive Workforce The.
Hale & Tempest Bangladesh Pharma Industry Dr. Brian W Tempest UNCTAD Investment Policy Review of Bangladesh United Nations Palais.
COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, COMMUNICATION TO THE SPRING EUROPEAN COUNCIL Working together for growth and jobs A new start.
The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Manila – 29.
Hale & Tempest Exploring the Structural Changes in the Global Pharmaceutical Marketplace Dr. Brian W Tempest MAPE Fund Managers Conference.
Hale & Tempest A View from India Dr. Brian W Tempest Opinion Formers’ Conference on Intellectual Property for Better Health Wellcome.
India – a growing player Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited Frankfurt – 15 th March’06.
Investor Presentation1 Creating Lasting Value Investor Presentation June 2009.
Fortis Healthcare Limited Earnings Call – Q2 – FY09.
Hale & Tempest Bangladesh Pharma Industry Dr. Brian W Tempest UNCTAD Investment Policy Review of Bangladesh United Nations Palais.
Hale & Tempest Indian Drug Discovery Dr. Brian W Tempest Asia Pacific Technology Network Tuesday 3 April 2012.
Hale & Tempest Mergers, Acquisitions & Alliances in Emerging Markets Dr. Brian W Tempest Generics & Biosimilars, CpHI Conference Istanbul,
Hale & Tempest Doing Business in Russia - the View from Overseas Dr. Brian W Tempest CpHI St Petersburg, Russia 17 April 2014.
Partnering Opportunities in India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Bio-Partnering.
Succeeding in Japan Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India India Japan Initiative.
Tazeem Pasha SelectUSA U.S. Department of Commerce Washington, DC Foreign Direct Investment in the United States 1SelectUSA.gov.
Hale & Tempest How a Major Indian Generic Company went Global Dr. Brian W Tempest Shanghai, China 18 November 2011.
India – The Pharma Advantage Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Tokyo –
Islamic Republic of Iran’s investment climate in high technologies FORUM NEW TECHNOLOGIES AUSTRIA - IRAN Austrian Federal Economic Chamber Thursday,
Hale & Tempest Consultation of Experts to discuss the WHO role in facilitating access to quality, affordable biotherapeutics (monoclonal antibodies & biosimilars.
Trends in the Pharmaceutical Industry and the Potential Impact on Future Innovation and Access to Medicines Dr. Brian W Tempest Pharmaceuticals.
Global Manufacturing – India
Innovation Development Strategy
Important Points The pharmaceutical industry in India ranks 3rd in the world terms of volume and 14th in terms of value.India’s cost of production is.
The intra and inter-firm geography of EMNCs: India’s pharmaceuticals
MASTEK ANALYST MEET JULY 2004
Choosing the Licensing Strategy for Every Stage of Drug Development
Presentation transcript:

Advantages of India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India India Clinical Trials Outsourcing Mumbai, India – Monday 23 rd July 2007

Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “may”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “seek to”, “future”, “objective”, “goal”, “likely”, “project”, “should”, “potential”, “will pursue” and similar expressions or variations of such expressions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. Ranbaxy does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof. Disclaimer

Asia’s Share of the World GDP (at PPP in %) Year China 17% 9% 5% 5% 12% India 12% 8% 4% 3% 5% Japan 2% 3% 3% 8% 7% Rest of Asia 7% 5% 7% 9% 13% Total Asia 38% 25% 19% 25% 37% Source – WEF - was 59% in 1820 with India 16%, China 33%

Davos Source – FT

The Productivity Advantage Indiaa usa Pharma view USA 1 chemist Better education x chemist 70 hours/week Longer working time x hours/week $ 800 monthly Lower cost x 20 $ 12,000 monthly Sources: IPHMR Conferences, New Delhi August 2004

 Japan - by % > 65 years from 19% in 2005  China - one child families, get older before becoming wealthy - labour costs will rise owing to labour shortage  India - India already has the youngest labour force in the world - source of the extra needed global workforce - India will pass China in total population in By 2013 India will have more young workers than China The Ageing Advantage Working Population, years In millions

 Growth - Japan, sustain current growth - China, slightly slower growth to prevent hard landing - India, increasing growth rate being talked up to 9%/10%  Sentiment - India, largest foreign affairs caucus in US Congress (180), nuclear deal - China, 74,000 demonstrations reported in 2005 in China. State secrecy, IP The Economic Growth Advantage

A race to prosperity

 The world has over 800 billionaires  USA has almost half  India - 36 billionaires  China - 15 billionaires  Net worth of 40 richest Indians - $170 b  40 richest Chinese - $38b Source: Forbes, Asia November 27, 2006 “2006 belongs to some of the emerging markets, and no country more than India” The Billionaires Advantage

The R&D Investment Advantage Most attractive R&D Investment locations: Ranked 3 rd - China, USA, India, Japan & UK Source – UNCTAD 2005 Reasons why India:  Qualified Scientists & Engineers  Global India players with Alliances  English speaking  TRIPs compliant – first patent March 2006  IIT, IIM & other scientific institutions Source – UNCTAD 2005

 4 th largest reservoir of Scientific Manpower (2 nd largest English speaking)  3m graduates pa, 115k MSc Chemistry (3.5k UK), 215k Eng (222k USA) Physics the most popular subject  Lead by a Nuclear Scientist as President – remote sensing satellite technology, 1/6 countries  PCT application ranked 3 rd – Kor, Chi, Ind, Sin, RSA  “US & Europe will not dominate Science, Maths, IT industries” – Mr. Bill Gates The Education Advantage

Science Education in EU “This means that when pupils are in a science laboratory their experience is unsafe, unsatisfactory or uninspiring for 65% of the time.” Source: Royal Society of Chemistry, Policy Bulletin – Spring 2006 UK “A” Level entries:Closed UK University % change Chemistry Departments: Physics : 32,059 28, % Dundee Kings Chemistry: 40,856 38,851 -5% Surrey Exeter Maths: 67,036 52, % Lancaster Queen Mary Computing: 19,099 7, % Source: Daily Mail – 11 August 2006 Only pupils at private schools can take physics, chemistry & biology separately Source: Times, 9 th November 2006

Number of Higher Education Institutions 05/06 18, % 00/01 11,412 90/01 5,932 80/01 4,861 Source: Indian University Grants Commission Science Education in India Number of Students enrolled in Higher Education Institutions 05/06 10, % 00/01 7,500 90/01 4,000 80/01 3,000 Source: Indian University Grants Commission Number of Institutions courses 05/06 99/00 Pharmacy % Medicine % Physiotherapy % Source: Pavan Agarwal (2006) based on data from professional councils PhD Degree awarded in Science 03/ % 00/ / (USA 03/04 25,000) Source: Indian University Grants Committee

The Education Advantage Engineers/Science graduates p.a – India 0.7m, China 0.5m, EU 0.5m, USA 0.4m, Japan 0.3m

 34 News TV channels. Oldest 13 years old (NDTV)  5000 newspapers, circulation 17m. 12 with 1m copies each.200m daily readers. 21m new daily readers 2003/2005, +14% with 50% rural and 50% urban readership  Diaspora network (25m across 120 countries)  Indians are hungry for information The Information Advantage Internet Usage – Asia 1.China123 m 2.Japan 86 m 3.India 51 m 4.S.Korea 34 m Source: Business Today, Sept. 24, 2006 Mobile Phones 1.China421 m 2.USA190 m 3.Japan157 m 4.Russia148 m 5.India116 m Source: Times of India, Sept. 14, 2006

The Pharma Plants Advantage Active Pharmaceuticals Facility, MohaliDosage Forms Facility, Paonta Sahib

The Pharma R&D Advantage Ranbaxy’s Patent Filings Clinical data management An Indian speciality 300 staff GSK -2.2m clinical data sheets -450 trials -Error rate <0.01/100k -No data security issues Source: BCG report ‘Looking Eastward Sep’2006’ R&D hotbeds “China & India have become R&D hotbeds……….. MNCs already operate some 180 R&D centres in China and More than 100 in India” Source: BCG report ‘Looking Eastward Sep’2006’ PCT Filers from Developing Countires Huawei – China6. ZTE – China 2.LG – Korea7. STR – Singapore 3.Samsung – Korea8. Ranbaxy – India 4.LG Chem – Korea9. CSIR – India 5.Elec Telecom – Korea10. NHN – Korea Source: WIPRO

Cost Advantage China India Cost Patients/site Based on USA at 100 Index Source: BCG report ‘Looking Forward 2006’ CountryUSAIndia Sites228 Subject Source: Andy Lee Pfizer Global, head clinical study and data management.Business India, August 13, 2006 “………..The Country’s World Class skills in Chemistry & IT and it’s large treatment naive patient population provides added allure” Boston Consultancy Group Harnessing the power of India 2006 The Pharma Clinical Advantage Medical Tourism Cardiac Surgery$000s USA30 Singapore20 Thailand14 India5-7 Source: Business world, 18 th Dec’2006 Patients - Naïve untreated patients - HIV50m - Diabetes32m - HT5m

India FDI 2003/4$4.3b 2004/5$5.6b 2005/6$6.0b Source: Outlook business June 2006 The Investment Advantage 2005 FDI Brazil$15bUK$164 b Russia$14bUSA$ 99 b India$6b China$72b (+$35b) Source: UNCTAD India on target for $12b in 2006/07 - But still small

Investment in India is rising

 More Privatization – public sector not so buoyant  Scope for improvement of Government Policies  Manufacturing growth versus China  GDP dynamics: Agriculture 31%20% - Industry28%26% - Services41%54%  Further encouragement of R&D for Pharmaceuticals The Potential for Improvement Advantage

Corporates continue to need Support

 More Privatization – public sector not so buoyant  Scope for improvement of Government Policies  Manufacturing growth versus China  GDP dynamics: Agriculture 31%20% - Industry28%26% - Services41%54%  Further encouragement of R&D for Pharmaceuticals The Potential for Improvement Advantage

 Microsoft Global Development Centre (GDCI)  Microsoft Global Services (MGSI)  Microsoft Global Technical Support Centre (GTSC)  Microsoft Systems Research (MSRI)  Microsoft India Development Centre (MIDC) Investment by Microsoft in India

A Global Strategic Asset for developed World Market businesses India

Generics – API’s USA DMF filings by India Source: Crisil / US FDA / J P Morgan % Share of USA DMF filings India China % 9% % 10% % 14% Q4’06 47% 9% Source: US FDA / J P Morgan, 6 th August 2006 Source: US FDA, Credit Suisse

- One in every four ANDAs filed by Indian Companies in top USA FDA filers Source: KPMG - No Chinese generic company has yet filed a USA FDA ANDA but expected in 2008 Generics - ANDAs ANDA Filings in USA by Indian Companies

Discovery – Local vendors available in India to Support Discovery Research Vendor Availability India China Analog preparation4125 Combinatorial chemistry377 Analytical chemistry377 Structural chemistry265 Assay development262 Computer drug design2613 High throughput Screening112 Bio informatics137 Genetically modified animals03 Basic molecular biology1325 Source – BCG, ‘Looking Eastwards, September 2006’ * Out of 90 vendors in October 2005

Discovery – Local vendors available in India to Support Clinical Research Contract Research Organisations30 Bio-equivalence & Bio-analytical15 Data Management & enabled services14 Site Management Organisations5 Central Laboratories8 Storage & Distribution5 Centralised ECG Services2 Clinical Research Training8 Source – Pharmaceutical Technology Asia Pacific, March 2007

Patient Recruitment

The Global challenge between India & China

The Tempest Crystal Ball – India & China Post TRIPs new products will dry up in India by Under this pressure Indian companies will adopt different business models The global generic industry will be dominated by India Discovery companies will continue to be attracted to India China will be perceived to be stronger in biology/ toxicology Alliances between Western Biotech and Indian companies will expand It will be India & China - and not India or China.

“The Indian System looks ramshackle and improvised. But at its best it is capable of brilliance” “When we say the Silicon Valley is built on ICs we don’t mean integrated circuits – we mean Indians & Chinese” “The UK needs to wake up to what India is becoming” Source: DEMOS report – January 2007 Perceptions of India

Key Challenges to the Indian Scenario

Potential Challenge – Asian Flu* *50% of world chickens bred in Asia

Potential challenge – Oil prices Source – Assocham A war against Iran could drive oil > $200 a barrel - ‘Times’ 22 nd June 2006 India is expected to import 85% of crude oil by 2012 from 70% today Source – BP

CO 2 emission - % of World total in USA23% EU 2517% China14% Russia7% Japan5% India4% – source: WRI, EIA Potential Challenge – Climate Change

Potential Challenge – Infrastructure Source – Manmohan Singh “Our greatest potential will be realised only if we can ensure that our Infrastructure does not become a severe and critical handicap”

Potential Challenge – over the border

Asia economic strength is returning to levels seen in the past Many advantages for India – Demographics, Education India is a global strategic asset for developed markets Some “Challenges” – infrastructure, climate change The current feeling in Indian Boardrooms is that a turning point has been reached, a tipping point has been passed and India’s time has arrived India is a rich location for future alliances and CT outsourcing MNCs will dip in& out of India & China, using their individual strengths “China & India represent the future of Asia and quite possibly the future for the global economy” – Steve Roach, Morgan Stanley Summary

Thank You